Onconase
information and resources from the National Cancer Institute
NCI Thesaurus | Onconase
(Other name for: ranpirnase)NCI Thesaurus | Onconase
(Other name for: ranpirnase)
|
|
|
|
news articles
Alfacell achieves full patient enrollment for Onconase phase IIIb ... Mar 28, 2006
Therapeutics Daily (subscription) (press release), ...full enrollment target of 316 patients has been reached for the international, confirmatory phase IIIb registration trial evaluating Onconase (ranpirnase), the ...
Alfacell Achieves Full Patient Enrollment Milestone for the ... Feb 27, 2006
PR Newswire (press release), ...the full enrollment target of 316 patients has been reached for the international, confirmatory Phase IIIb registration trial evaluating ONCONASE(R) (ranpirnase ...
Alfacell Corporation to Present at Leading European Cancer ... Mar 28, 2006
Yahoo! News (press release) ...in collaboration with Alfacell during her tenure at the National Cancer Institute (NCI) on a novel chemical conjugate coupling ONCONASE® (ranpirnase) with an ...
Alfacell Corporation Reports Second Quarter 2006 Financial Results ... Mar 21, 2006
Yahoo! News (press release) We also remain confident that we will successfully complete all regulatory requirements necessary to gain marketing approval of ONCONASE in the US, EU and ...
Spectrum takes part in cancer drug test Mar 20, 2006
The Grand Rapids Press, Pawl said researchers hope the drug, Onconase, will give patients who have had an unsuccessful round of chemotherapy additional time and a better quality of ...
Alfacell Corporation Announces Annual Shareholders Meeting Dec 6, 2005
PR Newswire (press release), The agenda is expected to include the election of the Company's new Board of Directors; updates from the management team on the ONCONASE(R) (ranpirnase ...
Alfacell Corporation Launches New Investor Relations Section of ... Nov 28, 2005
PR Newswire (press release), ONCONASE(R) (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration ...
|
|
